drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01041 | DB11793 | 770 | 738 | [
"DDInter1789",
"DDInter1297"
] | Thalidomide | Niraparib | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
770,
24,
738
]
],
[
[
770,
24,
1213
],
[
1213,
24,
738
]
],
[
[
770,
64,
663
],
[
663,
24,
738
]
],
[
[
770,
63,
1253
],
[
1253,
... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Thalidomide may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may cau... |
DB00554 | DB01225 | 1,027 | 500 | [
"DDInter1478",
"DDInter645"
] | Piroxicam | Enoxaparin | A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. | Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the inc... | Major | 2 | [
[
[
1027,
25,
500
]
],
[
[
1027,
24,
1039
],
[
1039,
24,
500
]
],
[
[
1027,
63,
305
],
[
305,
24,
500
]
],
[
[
1027,
24,
738
],
[
738,
... | [
[
[
"Piroxicam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
]
],
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenf... | Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Enoxaparin
Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase ... |
DB01067 | DB09046 | 959 | 1,094 | [
"DDInter826",
"DDInter1201"
] | Glipizide | Metreleptin | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy. Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. Complications of lipodystrophy ... | Moderate | 1 | [
[
[
959,
24,
1094
]
],
[
[
959,
63,
168
],
[
168,
23,
1094
]
],
[
[
959,
24,
1254
],
[
1254,
24,
1094
]
],
[
[
959,
24,
517
],
[
517,
... | [
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metreleptin"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Metreleptin
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and In... |
DB00691 | DB01097 | 1,058 | 1,377 | [
"DDInter1237",
"DDInter1033"
] | Moexipril | Leflunomide | Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney prob... | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
1058,
25,
1377
]
],
[
[
1058,
24,
959
],
[
959,
24,
1377
]
],
[
[
1058,
24,
1411
],
[
1411,
63,
1377
]
],
[
[
1058,
63,
590
],
[
590,
... | [
[
[
"Moexipril",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Moexipril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
... | Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutam... |
DB00317 | DB15328 | 883 | 829 | [
"DDInter810",
"DDInter1896"
] | Gefitinib | Ubrogepant | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor ... | Moderate | 1 | [
[
[
883,
24,
829
]
],
[
[
883,
24,
1476
],
[
1476,
24,
829
]
],
[
[
883,
40,
26
],
[
26,
24,
829
]
],
[
[
883,
35,
392
],
[
392,
24,... | [
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ubrogepant"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
... | Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Gefitinib (Compound) resembles Afatinib (Compound) and Afatinib may cause a moderate interaction that could exace... |
DB00261 | DB01177 | 702 | 77 | [
"DDInter93",
"DDInter904"
] | Anagrelide | Idarubicin | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Major | 2 | [
[
[
702,
25,
77
]
],
[
[
702,
5,
11555
],
[
11555,
44,
77
]
],
[
[
702,
7,
8683
],
[
8683,
46,
77
]
],
[
[
702,
18,
9205
],
[
9205,
... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idarubicin"
]
],
[
[
"Anagrelide",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease) is treated b... | Anagrelide (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Idarubicin (Compound)
Anagrelide (Compound) upregulates RBM15B (Gene) and RBM15B (Gene) is upregulated by Idarubicin (Compound)
Anagrelide (Compound) downregulates IFRD2 (Gene) and IFRD2 (Gene) is downregulated by I... |
DB00637 | DB09048 | 1,557 | 555 | [
"DDInter128",
"DDInter1284"
] | Astemizole | Netupitant | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug i... | Moderate | 1 | [
[
[
1557,
24,
555
]
],
[
[
1557,
63,
1101
],
[
1101,
23,
555
]
],
[
[
1557,
24,
283
],
[
283,
62,
555
]
],
[
[
1557,
24,
1133
],
[
1133,
... | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Netupitant"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Netupitant
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratin... |
DB00637 | DB05316 | 1,557 | 749 | [
"DDInter128",
"DDInter1467"
] | Astemizole | Pimavanserin | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. Unlike other atypical antipsychotic... | Moderate | 1 | [
[
[
1557,
24,
749
]
],
[
[
1557,
23,
112
],
[
112,
23,
749
]
],
[
[
1557,
24,
1264
],
[
1264,
24,
749
]
],
[
[
1557,
63,
521
],
[
521,
... | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pimavanserin"
]
],
[
[
"Astemizole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[... | Astemizole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pimavanserin
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxep... |
DB00431 | DB09122 | 1,503 | 1,613 | [
"DDInter1072",
"DDInter1409"
] | Lindane | Peginterferon beta-1a | An organochlorine insecticide that has been used as a pediculicide and a scabicide. Lindane has been banned in California, United Kingdom, Australia, and many western countries due to concerns about neurotoxicity and adverse effects on the environment. In Canada, Lindane is not recommmended as a first-line therapy due ... | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
1503,
24,
1613
]
],
[
[
1503,
24,
795
],
[
795,
24,
1613
]
],
[
[
1503,
63,
1176
],
[
1176,
24,
1613
]
],
[
[
1503,
24,
1383
],
[
1383... | [
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pemoline"
],
[... | Lindane may cause a moderate interaction that could exacerbate diseases when taken with Pemoline and Pemoline may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Mox... |
DB00669 | DB00757 | 399 | 1,166 | [
"DDInter1730",
"DDInter581"
] | Sumatriptan | Dolasetron | Sumatriptan is a serotonin receptor agonist commonly used to treat migraines and sometimes cluster headaches.[L6793,L6796,L6799,L6805,L6808,L6811] Sumatriptan is the first of the triptans and was made available in Europe in 1991 to treat migraines. Sumatriptan was granted FDA approval on 28 December 1992. | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Major | 2 | [
[
[
399,
25,
1166
]
],
[
[
399,
6,
17589
],
[
17589,
45,
1166
]
],
[
[
399,
21,
28803
],
[
28803,
60,
1166
]
],
[
[
399,
63,
475
],
[
475,... | [
[
[
"Sumatriptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
]
],
[
[
"Sumatriptan",
"{u} (Compound) binds {v} (Gene)",
"HTR3A"
],
[
"HTR3A",
"{u} (Gene) is bound by {v} (Compound)",
"Dolaset... | Sumatriptan (Compound) binds HTR3A (Gene) and HTR3A (Gene) is bound by Dolasetron (Compound)
Sumatriptan (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Dolasetron (Compound)
Sumatriptan may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine ... |
DB00912 | DB01611 | 473 | 1,487 | [
"DDInter1581",
"DDInter893"
] | Repaglinide | Hydroxychloroquine | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Moderate | 1 | [
[
[
473,
24,
1487
]
],
[
[
473,
21,
28658
],
[
28658,
60,
1487
]
],
[
[
473,
24,
1247
],
[
1247,
23,
1487
]
],
[
[
473,
63,
88
],
[
88,
... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Repaglinide",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect)... | Repaglinide (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Hydroxychloroquine (Compound)
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when ... |
DB00353 | DB08865 | 588 | 1,593 | [
"DDInter1187",
"DDInter448"
] | Methylergometrine | Crizotinib | A homolog of ergonovine containing one more CH2 group. (Merck Index, 11th ed) | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Moderate | 1 | [
[
[
588,
24,
1593
]
],
[
[
588,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
588,
18,
6095
],
[
6095,
46,
1593
]
],
[
[
588,
7,
4333
],
[
4333,
... | [
[
[
"Methylergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Methylergometrine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v... | Methylergometrine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Methylergometrine (Compound) downregulates TCEAL4 (Gene) and TCEAL4 (Gene) is upregulated by Crizotinib (Compound)
Methylergometrine (Compound) upregulates MEF2C (Gene) and MEF2C (Gene) is upregulated by Crizotinib (Com... |
DB06414 | DB11581 | 655 | 1,456 | [
"DDInter703",
"DDInter1926"
] | Etravirine | Venetoclax | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Major | 2 | [
[
[
655,
25,
1456
]
],
[
[
655,
24,
1135
],
[
1135,
23,
1456
]
],
[
[
655,
25,
1476
],
[
1476,
63,
1456
]
],
[
[
655,
63,
86
],
[
86,
... | [
[
[
"Etravirine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
]
],
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",... | Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Venetoclax
Etravirine may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a mo... |
DB00657 | DB01390 | 1,360 | 1,117 | [
"DDInter1130",
"DDInter1683"
] | Mecamylamine | Sodium bicarbonate | A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool. | Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions. | Moderate | 1 | [
[
[
1360,
24,
1117
]
],
[
[
1360,
21,
29093
],
[
29093,
60,
1117
]
],
[
[
1360,
24,
22
],
[
22,
24,
1117
]
],
[
[
1360,
21,
29093
],
[
290... | [
[
[
"Mecamylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Mecamylamine",
"{u} (Compound) causes {v} (Side Effect)",
"Fatigue"
],
[
"Fatigue",
"{u} (Side Effect)... | Mecamylamine (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Sodium bicarbonate (Compound)
Mecamylamine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with S... |
DB00731 | DB01039 | 1,144 | 535 | [
"DDInter1269",
"DDInter718"
] | Nateglinide | Fenofibrate | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Fenofibrate is a fibric acid derivative like [clofibrate] and [gemfibrozil]. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.[L8588,L8591] Fenofibrate was granted FDA approval on 31 December 1993. | Moderate | 1 | [
[
[
1144,
24,
535
]
],
[
[
1144,
63,
831
],
[
831,
1,
535
]
],
[
[
1144,
6,
8374
],
[
8374,
45,
535
]
],
[
[
1144,
21,
28936
],
[
28936,
... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenofibrate"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indomethacin"
],
... | Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin (Compound) resembles Fenofibrate (Compound)
Nateglinide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fenofibrate (Compound)
Nateglinide (Compound) causes Hyperhidrosis (Side Effect) ... |
DB08881 | DB15328 | 868 | 829 | [
"DDInter1925",
"DDInter1896"
] | Vemurafenib | Ubrogepant | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor ... | Moderate | 1 | [
[
[
868,
24,
829
]
],
[
[
868,
24,
1476
],
[
1476,
24,
829
]
],
[
[
868,
63,
578
],
[
578,
24,
829
]
],
[
[
868,
25,
124
],
[
124,
2... | [
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ubrogepant"
]
],
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
... | Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Tica... |
DB00835 | DB09293 | 100 | 116 | [
"DDInter245",
"DDInter954"
] | Brompheniramine | Iodide I-131 | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. Iodine-131 is notable for causing mutation and death in cells that it penetrates, which is due to its mode of beta decay. As a result of beta decay, approximately 10% of its energy and radiation do... | Moderate | 1 | [
[
[
100,
24,
116
]
],
[
[
100,
63,
701
],
[
701,
24,
116
]
],
[
[
100,
24,
516
],
[
516,
24,
116
]
],
[
[
100,
35,
849
],
[
849,
24,... | [
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
],
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
... | Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Levocetir... |
DB00206 | DB01222 | 1,245 | 617 | [
"DDInter1582",
"DDInter246"
] | Reserpine | Budesonide | An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a rese... | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Moderate | 1 | [
[
[
1245,
24,
617
]
],
[
[
1245,
24,
251
],
[
251,
1,
617
]
],
[
[
1245,
7,
7669
],
[
7669,
46,
617
]
],
[
[
1245,
18,
4112
],
[
4112,
... | [
[
[
"Reserpine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
]
],
[
[
"Reserpine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[
... | Reserpine may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Budesonide (Compound)
Reserpine (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Budesonide (Compound)
Reserpine (Compound) downregulates AURKB (Gene) and ... |
DB00048 | DB00254 | 1,595 | 964 | [
"DDInter435",
"DDInter598"
] | Collagenase clostridium histolyticum | Doxycycline | Collagenase clostridium histolyticum is an enzyme produced by the bacterium Clostridium histolyticum. It is beneficial in the breakdown of collagen plaques for the treatment of Dupuytren's contracture and Peyronie's disease. The topical formulation is used for the debridement of necrotic tissue due to burns or chronic ... | Doxycycline is a broad-spectrum antibiotic synthetically derived from [oxytetracycline]. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and... | Moderate | 1 | [
[
[
1595,
24,
964
]
],
[
[
1595,
24,
1572
],
[
1572,
40,
964
]
],
[
[
1595,
24,
1620
],
[
1620,
1,
964
]
],
[
[
1595,
24,
279
],
[
279,
... | [
[
[
"Collagenase clostridium histolyticum",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxycycline"
]
],
[
[
"Collagenase clostridium histolyticum",
"{u} may cause a moderate interaction that could exacerbate diseases whe... | Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when taken with Demeclocycline and Demeclocycline (Compound) resembles Doxycycline (Compound)
Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when taken with Tetracyc... |
DB00881 | DB08938 | 954 | 1,384 | [
"DDInter1554",
"DDInter1112"
] | Quinapril | Magaldrate | Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta b... | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Minor | 0 | [
[
[
954,
23,
1384
]
],
[
[
954,
63,
167
],
[
167,
23,
1384
]
],
[
[
954,
1,
1523
],
[
1523,
23,
1384
]
],
[
[
954,
24,
1220
],
[
1220,
... | [
[
[
"Quinapril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
... | Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Quinapril (Compound) resembles Labetalol (Compound) and Labetalol may cause a minor interaction that can li... |
DB11979 | DB12825 | 1,320 | 1,375 | [
"DDInter625",
"DDInter1032"
] | Elagolix | Lefamulin | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Moderate | 1 | [
[
[
1320,
24,
1375
]
],
[
[
1320,
24,
159
],
[
159,
63,
1375
]
],
[
[
1320,
63,
309
],
[
309,
24,
1375
]
],
[
[
1320,
24,
1033
],
[
1033,
... | [
[
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
... | Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixab... |
DB00446 | DB09331 | 597 | 745 | [
"DDInter351",
"DDInter478"
] | Chloramphenicol | Daratumumab | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind. Daratumumab was granted FDA approval on 16 November 2015. It is approved for the trea... | Moderate | 1 | [
[
[
597,
24,
745
]
],
[
[
597,
24,
139
],
[
139,
24,
745
]
],
[
[
597,
63,
599
],
[
599,
24,
745
]
],
[
[
597,
24,
270
],
[
270,
63,... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daratumumab"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Daratumumab
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzuma... |
DB01165 | DB09104 | 1,539 | 286 | [
"DDInter1325",
"DDInter1118"
] | Ofloxacin | Magnesium hydroxide | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
1539,
24,
286
]
],
[
[
1539,
24,
820
],
[
820,
23,
286
]
],
[
[
1539,
63,
401
],
[
401,
23,
286
]
],
[
[
1539,
62,
60
],
[
60,
2... | [
[
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
... | Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine a... |
DB00289 | DB01041 | 847 | 770 | [
"DDInter132",
"DDInter1789"
] | Atomoxetine | Thalidomide | Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve develop... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
847,
24,
770
]
],
[
[
847,
6,
10215
],
[
10215,
45,
770
]
],
[
[
847,
21,
28789
],
[
28789,
60,
770
]
],
[
[
847,
24,
609
],
[
609,
... | [
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Atomoxetine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compou... | Atomoxetine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Thalidomide (Compound)
Atomoxetine (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Thalidomide (Compound)
Atomoxetine may cause a moderate interaction that could exacerbate diseases when... |
DB08870 | DB15066 | 850 | 445 | [
"DDInter228",
"DDInter821"
] | Brentuximab vedotin | Givosiran | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a... | Moderate | 1 | [
[
[
850,
24,
445
]
],
[
[
850,
63,
1555
],
[
1555,
24,
445
]
],
[
[
850,
64,
329
],
[
329,
24,
445
]
],
[
[
850,
24,
1613
],
[
1613,
... | [
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplati... | Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Brentuximab vedotin may lead to a major life threatening interaction when taken with Bleomycin and Ble... |
DB06779 | DB09079 | 365 | 1,496 | [
"DDInter470",
"DDInter1296"
] | Dalteparin | Nintedanib | Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the r... | Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis trea... | Moderate | 1 | [
[
[
365,
24,
1496
]
],
[
[
365,
64,
707
],
[
707,
24,
1496
]
],
[
[
365,
24,
1412
],
[
1412,
63,
1496
]
],
[
[
365,
25,
840
],
[
840,
... | [
[
[
"Dalteparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Dalteparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
],
[
"Danaparoid... | Dalteparin may lead to a major life threatening interaction when taken with Danaparoid and Danaparoid may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Dalteparin may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol and Calaspargase ... |
DB00543 | DB09082 | 87 | 659 | [
"DDInter82",
"DDInter1934"
] | Amoxapine | Vilanterol | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, am... | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
87,
24,
659
]
],
[
[
87,
24,
927
],
[
927,
63,
659
]
],
[
[
87,
25,
1069
],
[
1069,
24,
659
]
],
[
[
87,
24,
959
],
[
959,
24,
... | [
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
... | Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Amoxapine may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may cause ... |
DB00197 | DB06717 | 1,324 | 875 | [
"DDInter1881",
"DDInter778"
] | Troglitazone | Fosaprepitant | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Moderate | 1 | [
[
[
1324,
24,
875
]
],
[
[
1324,
24,
723
],
[
723,
1,
875
]
],
[
[
1324,
24,
222
],
[
222,
23,
875
]
],
[
[
1324,
24,
466
],
[
466,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant (Compound) resembles Fosaprepitant (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that... |
DB00365 | DB00853 | 839 | 1,686 | [
"DDInter842",
"DDInter1762"
] | Grepafloxacin | Temozolomide | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alky... | Minor | 0 | [
[
[
839,
23,
1686
]
],
[
[
839,
23,
970
],
[
970,
24,
1686
]
],
[
[
839,
24,
1419
],
[
1419,
24,
1686
]
],
[
[
839,
62,
377
],
[
377,
... | [
[
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Temozolomide"
]
],
[
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fluorouracil"
],
... | Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Fluorouracil and Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Temozolomide
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Imatinib an... |
DB01032 | DB01050 | 824 | 848 | [
"DDInter1522",
"DDInter900"
] | Probenecid | Ibuprofen | The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy. | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Minor | 0 | [
[
[
824,
23,
848
]
],
[
[
824,
6,
1829
],
[
1829,
45,
848
]
],
[
[
824,
21,
28864
],
[
28864,
60,
848
]
],
[
[
824,
62,
1559
],
[
1559,
... | [
[
[
"Probenecid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ibuprofen"
]
],
[
[
"Probenecid",
"{u} (Compound) binds {v} (Gene)",
"ALB"
],
[
"ALB",
"{u} (Gene) is bound by {v} (Compound)",
"I... | Probenecid (Compound) binds ALB (Gene) and ALB (Gene) is bound by Ibuprofen (Compound)
Probenecid (Compound) causes Erythema multiforme (Side Effect) and Erythema multiforme (Side Effect) is caused by Ibuprofen (Compound)
Probenecid may cause a minor interaction that can limit clinical effects when taken with Famotidin... |
DB00491 | DB00574 | 127 | 121 | [
"DDInter1217",
"DDInter717"
] | Miglitol | Fenfluramine | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the bod... | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Moderate | 1 | [
[
[
127,
24,
121
]
],
[
[
127,
24,
659
],
[
659,
63,
121
]
],
[
[
127,
63,
176
],
[
176,
24,
121
]
],
[
[
127,
24,
341
],
[
341,
64,... | [
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
... | Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and In... |
DB00704 | DB11652 | 267 | 1,155 | [
"DDInter1263",
"DDInter1891"
] | Naltrexone | Tucatinib | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Moderate | 1 | [
[
[
267,
24,
1155
]
],
[
[
267,
63,
1101
],
[
1101,
23,
1155
]
],
[
[
267,
24,
609
],
[
609,
24,
1155
]
],
[
[
267,
63,
522
],
[
522,
... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clari... |
DB01211 | DB06605 | 609 | 1,409 | [
"DDInter393",
"DDInter108"
] | Clarithromycin | Apixaban | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Moderate | 1 | [
[
[
609,
24,
1409
]
],
[
[
609,
6,
10215
],
[
10215,
45,
1409
]
],
[
[
609,
21,
29061
],
[
29061,
60,
1409
]
],
[
[
609,
62,
307
],
[
307,... | [
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Clarithromycin",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Com... | Clarithromycin (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Apixaban (Compound)
Clarithromycin (Compound) causes Gamma-glutamyltransferase increased (Side Effect) and Gamma-glutamyltransferase increased (Side Effect) is caused by Apixaban (Compound)
Clarithromycin may cause a minor interaction that ca... |
DB00889 | DB01611 | 1,133 | 1,487 | [
"DDInter840",
"DDInter893"
] | Granisetron | Hydroxychloroquine | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Major | 2 | [
[
[
1133,
25,
1487
]
],
[
[
1133,
24,
1520
],
[
1520,
25,
1487
]
],
[
[
1133,
6,
12523
],
[
12523,
45,
1487
]
],
[
[
1133,
21,
28658
],
[
... | [
[
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
],
[
"... | Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Primaquine and Primaquine may lead to a major life threatening interaction when taken with Hydroxychloroquine
Granisetron (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Hydroxychloroquine (Compound)
Granisetron (Co... |
DB00414 | DB01583 | 590 | 624 | [
"DDInter16",
"DDInter1075"
] | Acetohexamide | Liotrix | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Liotrix is a synthetically derived thyroid hormone replacement preparation. It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight. Liotrix was developed when it was believed that serum levels of both T4 and T3 were maintained by direct thyroidal s... | Moderate | 1 | [
[
[
590,
24,
624
]
],
[
[
590,
63,
1152
],
[
1152,
1,
624
]
],
[
[
590,
24,
542
],
[
542,
40,
624
]
],
[
[
590,
63,
417
],
[
417,
23... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liotrix"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
],
... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine (Compound) resembles Liotrix (Compound)
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine and Levothyroxine (Compound) resembles Liotrix (... |
DB09570 | DB11989 | 1,480 | 1,434 | [
"DDInter1002",
"DDInter183"
] | Ixazomib | Benznidazole | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017. It is the first treatment made available in the United States for Chagas disease. | Moderate | 1 | [
[
[
1480,
24,
1434
]
],
[
[
1480,
63,
788
],
[
788,
24,
1434
]
],
[
[
1480,
64,
375
],
[
375,
24,
1434
]
],
[
[
1480,
24,
148
],
[
148,
... | [
[
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benznidazole"
]
],
[
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
[
... | Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Ixazomib may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizuma... |
DB00280 | DB06616 | 494 | 594 | [
"DDInter575",
"DDInter224"
] | Disopyramide | Bosutinib | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Major | 2 | [
[
[
494,
25,
594
]
],
[
[
494,
6,
8374
],
[
8374,
45,
594
]
],
[
[
494,
21,
28709
],
[
28709,
60,
594
]
],
[
[
494,
23,
112
],
[
112,
... | [
[
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
]
],
[
[
"Disopyramide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Bosu... | Disopyramide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosutinib (Compound)
Disopyramide (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Bosutinib (Compound)
Disopyramide may cause a minor interaction that can limit clinical effects when taken with... |
DB00500 | DB00501 | 24 | 752 | [
"DDInter1831",
"DDInter380"
] | Tolmetin | Cimetidine | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Minor | 0 | [
[
[
24,
23,
752
]
],
[
[
24,
6,
10612
],
[
10612,
45,
752
]
],
[
[
24,
21,
29134
],
[
29134,
60,
752
]
],
[
[
24,
1,
831
],
[
831,
2... | [
[
[
"Tolmetin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
]
],
[
[
"Tolmetin",
"{u} (Compound) binds {v} (Gene)",
"SLC22A6"
],
[
"SLC22A6",
"{u} (Gene) is bound by {v} (Compound)",
... | Tolmetin (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Cimetidine (Compound)
Tolmetin (Compound) causes Flatulence (Side Effect) and Flatulence (Side Effect) is caused by Cimetidine (Compound)
Tolmetin (Compound) resembles Indomethacin (Compound) and Indomethacin may cause a minor interaction that can ... |
DB00242 | DB00480 | 1,064 | 1,668 | [
"DDInter392",
"DDInter1035"
] | Cladribine | Lenalidomide | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenali... | Major | 2 | [
[
[
1064,
25,
1668
]
],
[
[
1064,
25,
770
],
[
770,
40,
1668
]
],
[
[
1064,
5,
11555
],
[
11555,
44,
1668
]
],
[
[
1064,
7,
7720
],
[
7720... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenalidomide"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{... | Cladribine may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide (Compound) resembles Lenalidomide (Compound)
Cladribine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Lenalidomide (Compound)
Cladribine (Compound) upregulates PTGS2 (G... |
DB00759 | DB01226 | 1,620 | 1,319 | [
"DDInter1783",
"DDInter1235"
] | Tetracycline | Mivacurium | Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some e... | Mivacurium is a bisbenzylisoquinolinium based neuromuscular blocker or muscle relaxant. It binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission. | Moderate | 1 | [
[
[
1620,
24,
1319
]
],
[
[
1620,
63,
1031
],
[
1031,
24,
1319
]
],
[
[
1620,
23,
1311
],
[
1311,
63,
1319
]
],
[
[
1620,
1,
1669
],
[
166... | [
[
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mivacurium"
]
],
[
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
],
... | Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Mivacurium
Tetracycline may cause a minor interaction that can limit clinical effects when taken with Metoclopramide ... |
DB00022 | DB00099 | 268 | 440 | [
"DDInter1408",
"DDInter735"
] | Peginterferon alfa-2b | Filgrastim | Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the seq... | Moderate | 1 | [
[
[
268,
24,
440
]
],
[
[
268,
24,
1480
],
[
1480,
63,
440
]
],
[
[
268,
25,
1101
],
[
1101,
63,
440
]
],
[
[
268,
63,
1451
],
[
1451,
... | [
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Filgrastim"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazo... | Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim
Peginterferon alfa-2b may lead to a major life threatening interaction when taken with Bexarotene and Bex... |
DB00445 | DB01599 | 322 | 1,232 | [
"DDInter655",
"DDInter1523"
] | Epirubicin | Probucol | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993). | Moderate | 1 | [
[
[
322,
24,
1232
]
],
[
[
322,
7,
5182
],
[
5182,
45,
1232
]
],
[
[
322,
18,
8587
],
[
8587,
46,
1232
]
],
[
[
322,
23,
112
],
[
112,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Probucol"
]
],
[
[
"Epirubicin",
"{u} (Compound) upregulates {v} (Gene)",
"CES1"
],
[
"CES1",
"{u} (Gene) is bound by {v} (Compound)",... | Epirubicin (Compound) upregulates CES1 (Gene) and CES1 (Gene) is bound by Probucol (Compound)
Epirubicin (Compound) downregulates RRS1 (Gene) and RRS1 (Gene) is upregulated by Probucol (Compound)
Epirubicin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may... |
DB00398 | DB06403 | 79 | 1,204 | [
"DDInter1702",
"DDInter62"
] | Sorafenib | Ambrisentan | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Ambrisentan is an orally active selective type A endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening. In addition, it is approved in the Un... | Moderate | 1 | [
[
[
79,
24,
1204
]
],
[
[
79,
63,
600
],
[
600,
23,
1204
]
],
[
[
79,
24,
609
],
[
609,
23,
1204
]
],
[
[
79,
25,
868
],
[
868,
63,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ambrisentan"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
... | Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Ambrisentan
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Cla... |
DB00526 | DB15066 | 1,555 | 445 | [
"DDInter1355",
"DDInter821"
] | Oxaliplatin | Givosiran | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a... | Moderate | 1 | [
[
[
1555,
24,
445
]
],
[
[
1555,
24,
850
],
[
850,
24,
445
]
],
[
[
1555,
63,
589
],
[
589,
24,
445
]
],
[
[
1555,
64,
702
],
[
702,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Ci... |
DB00927 | DB11732 | 1,559 | 1,097 | [
"DDInter712",
"DDInter1027"
] | Famotidine | Lasmiditan | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.[L9338,L9356] It was also approved by the European Commission on August 17, 2022. Traditionally, the triptan class of anti-migraine medications (e.g. [sumatriptan]) have se... | Moderate | 1 | [
[
[
1559,
24,
1097
]
],
[
[
1559,
63,
1181
],
[
1181,
24,
1097
]
],
[
[
1559,
24,
971
],
[
971,
63,
1097
]
],
[
[
1559,
24,
77
],
[
77,
... | [
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terfenadine"
],
[
... | Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gi... |
DB08815 | DB13928 | 154 | 1,385 | [
"DDInter1104",
"DDInter1660"
] | Lurasidone | Semaglutide | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
154,
24,
1385
]
],
[
[
154,
63,
1154
],
[
1154,
24,
1385
]
],
[
[
154,
24,
1033
],
[
1033,
24,
1385
]
],
[
[
154,
64,
609
],
[
609,
... | [
[
[
"Lurasidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Lurasidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
],
[
... | Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpe... |
DB08880 | DB13873 | 1,510 | 1,534 | [
"DDInter1771",
"DDInter719"
] | Teriflunomide | Fenofibric acid | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Fenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia. It works to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, apolipoprotein B, while increasing high-density lipoprotein cholesterol.[A32038,L128... | Major | 2 | [
[
[
1510,
25,
1534
]
],
[
[
1510,
64,
267
],
[
267,
24,
1534
]
],
[
[
1510,
25,
1613
],
[
1613,
24,
1534
]
],
[
[
1510,
63,
1144
],
[
1144... | [
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fenofibric acid"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naltrexone"
],
[
"Naltrexone",
... | Teriflunomide may lead to a major life threatening interaction when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Fenofibric acid
Teriflunomide may lead to a major life threatening interaction when taken with Peginterferon beta-1a and Peginterferon ... |
DB01406 | DB08880 | 984 | 1,510 | [
"DDInter472",
"DDInter1771"
] | Danazol | Teriflunomide | A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders. | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
984,
25,
1510
]
],
[
[
984,
24,
129
],
[
129,
63,
1510
]
],
[
[
984,
63,
1144
],
[
1144,
24,
1510
]
],
[
[
984,
40,
1197
],
[
1197,
... | [
[
[
"Danazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Danazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamid... | Danazol may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Danazol may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nate... |
DB00427 | DB08815 | 1,233 | 154 | [
"DDInter1879",
"DDInter1104"
] | Triprolidine | Lurasidone | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Moderate | 1 | [
[
[
1233,
24,
154
]
],
[
[
1233,
24,
1532
],
[
1532,
24,
154
]
],
[
[
1233,
63,
1242
],
[
1242,
24,
154
]
],
[
[
1233,
24,
1609
],
[
1609,... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Ce... |
DB00902 | DB11130 | 104 | 407 | [
"DDInter1168",
"DDInter1344"
] | Methdilazine | Opium | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
104,
24,
407
]
],
[
[
104,
24,
409
],
[
409,
24,
407
]
],
[
[
104,
63,
556
],
[
556,
24,
407
]
],
[
[
104,
24,
418
],
[
418,
63,... | [
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Felodipine"
],
[
... | Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Felodipine and Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Valproic acid and Valp... |
DB00570 | DB14409 | 147 | 1,129 | [
"DDInter1936",
"DDInter867"
] | Vinblastine | Human adenovirus e serotype 4 strain cl-68578 antigen | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine. | Moderate | 1 | [
[
[
147,
24,
1129
]
],
[
[
147,
64,
1057
],
[
1057,
24,
1129
]
],
[
[
147,
24,
1683
],
[
1683,
24,
1129
]
],
[
[
147,
63,
134
],
[
134,
... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Vinblastine",
"{u} may lead to a major life threatening interaction when taken with {v}",
... | Vinblastine may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Vinblastine may cause a moderate interaction that could exacerbate diseases when ta... |
DB00193 | DB01041 | 534 | 770 | [
"DDInter1841",
"DDInter1789"
] | Tramadol | Thalidomide | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
534,
24,
770
]
],
[
[
534,
18,
20113
],
[
20113,
57,
770
]
],
[
[
534,
21,
29425
],
[
29425,
60,
770
]
],
[
[
534,
24,
609
],
[
609,
... | [
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Tramadol",
"{u} (Compound) downregulates {v} (Gene)",
"IER3"
],
[
"IER3",
"{u} (Gene) is downregulated by {v} (Co... | Tramadol (Compound) downregulates IER3 (Gene) and IER3 (Gene) is downregulated by Thalidomide (Compound)
Tramadol (Compound) causes Myocardial ischaemia (Side Effect) and Myocardial ischaemia (Side Effect) is caused by Thalidomide (Compound)
Tramadol may cause a moderate interaction that could exacerbate diseases when ... |
DB01259 | DB06402 | 392 | 1,079 | [
"DDInter1024",
"DDInter1756"
] | Lapatinib | Telavancin | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and sub... | Moderate | 1 | [
[
[
392,
24,
1079
]
],
[
[
392,
21,
28680
],
[
28680,
60,
1079
]
],
[
[
392,
62,
112
],
[
112,
23,
1079
]
],
[
[
392,
24,
657
],
[
657,
... | [
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
]
],
[
[
"Lapatinib",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (C... | Lapatinib (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Telavancin (Compound)
Lapatinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Telavancin
Lapati... |
DB00377 | DB11732 | 1,494 | 1,097 | [
"DDInter1382",
"DDInter1027"
] | Palonosetron | Lasmiditan | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.[L9338,L9356] It was also approved by the European Commission on August 17, 2022. Traditionally, the triptan class of anti-migraine medications (e.g. [sumatriptan]) have se... | Major | 2 | [
[
[
1494,
25,
1097
]
],
[
[
1494,
63,
1181
],
[
1181,
24,
1097
]
],
[
[
1494,
24,
971
],
[
971,
63,
1097
]
],
[
[
1494,
24,
77
],
[
77,
... | [
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lasmiditan"
]
],
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terfenadine"
],
[
"Terfe... | Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib an... |
DB00945 | DB01432 | 1,479 | 857 | [
"DDInter20",
"DDInter368"
] | Acetylsalicylic acid | Cholestyramine | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Cholestyramine or colestyramine is a bile acid sequestrant. Bile acid sequestrants are polymeric compounds which serve as ion exchange resins. Cholestyramine resin is quite hydrophilic, but insoluble in water. | Minor | 0 | [
[
[
1479,
23,
857
]
],
[
[
1479,
63,
1512
],
[
1512,
23,
857
]
],
[
[
1479,
24,
1411
],
[
1411,
24,
857
]
],
[
[
1479,
63,
870
],
[
870,
... | [
[
[
"Acetylsalicylic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cholestyramine"
]
],
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclo... | Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a minor interaction that can limit clinical effects when taken with Cholestyramine
Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00075 | DB11627 | 541 | 1,367 | [
"DDInter1250",
"DDInter860"
] | Muromonab | Hepatitis B Vaccine (Recombinant) | Murine monoclonal antibody specific to CD3 T-cell lymphocyte antigens. More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method. Muromonab is 93% monomeric immune globulin G type... | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, n... | Moderate | 1 | [
[
[
541,
24,
1367
]
],
[
[
541,
25,
1064
],
[
1064,
24,
1367
]
],
[
[
541,
24,
259
],
[
259,
24,
1367
]
],
[
[
541,
64,
581
],
[
581,
... | [
[
[
"Muromonab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Muromonab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
... | Muromonab may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Muromonab may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and ... |
DB00361 | DB15762 | 134 | 725 | [
"DDInter1939",
"DDInter1644"
] | Vinorelbine | Satralizumab | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to [tocilizumab], which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare au... | Moderate | 1 | [
[
[
134,
24,
725
]
],
[
[
134,
24,
1362
],
[
1362,
24,
725
]
],
[
[
134,
25,
384
],
[
384,
24,
725
]
],
[
[
134,
63,
58
],
[
58,
24,... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Satralizumab"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
... | Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab
Vinorelbine may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause ... |
DB00694 | DB08913 | 51 | 1,186 | [
"DDInter485",
"DDInter1561"
] | Daunorubicin | Radium Ra 223 dichloride | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first ap... | Moderate | 1 | [
[
[
51,
24,
1186
]
],
[
[
51,
21,
28872
],
[
28872,
60,
1186
]
],
[
[
51,
24,
37
],
[
37,
24,
1186
]
],
[
[
51,
63,
134
],
[
134,
24... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Daunorubicin",
"{u} (Compound) causes {v} (Side Effect)",
"Extravasation"
],
[
"Extravasation",
... | Daunorubicin (Compound) causes Extravasation (Side Effect) and Extravasation (Side Effect) is caused by Radium Ra 223 dichloride (Compound)
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Lomustine and Lomustine may cause a moderate interaction that could exacerbate diseases... |
DB00382 | DB00431 | 62 | 1,503 | [
"DDInter1734",
"DDInter1072"
] | Tacrine | Lindane | A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market. | An organochlorine insecticide that has been used as a pediculicide and a scabicide. Lindane has been banned in California, United Kingdom, Australia, and many western countries due to concerns about neurotoxicity and adverse effects on the environment. In Canada, Lindane is not recommmended as a first-line therapy due ... | Moderate | 1 | [
[
[
62,
24,
1503
]
],
[
[
62,
24,
1613
],
[
1613,
63,
1503
]
],
[
[
62,
63,
1031
],
[
1031,
24,
1503
]
],
[
[
62,
25,
593
],
[
593,
... | [
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lindane"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
],
[
... | Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Lindane
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Theophyl... |
DB04861 | DB12267 | 1,592 | 1,476 | [
"DDInter1271",
"DDInter233"
] | Nebivolol | Brigatinib | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
1592,
24,
1476
]
],
[
[
1592,
63,
176
],
[
176,
24,
1476
]
],
[
[
1592,
23,
578
],
[
578,
24,
1476
]
],
[
[
1592,
24,
1276
],
[
1276,
... | [
[
[
"Nebivolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Nebivolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
... | Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Nebivolol may cause a minor interaction that can limit clinical effects when taken with Ticagrelor an... |
DB11952 | DB11988 | 800 | 270 | [
"DDInter612",
"DDInter1321"
] | Duvelisib | Ocrelizumab | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Moderate | 1 | [
[
[
800,
24,
270
]
],
[
[
800,
63,
134
],
[
134,
24,
270
]
],
[
[
800,
64,
1019
],
[
1019,
24,
270
]
],
[
[
800,
24,
1619
],
[
1619,
... | [
[
[
"Duvelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Duvelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
... | Duvelisib may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Duvelisib may lead to a major life threatening interaction when taken with Deflazacort and Deflazacort may cau... |
DB01156 | DB01182 | 593 | 371 | [
"DDInter252",
"DDInter1534"
] | Bupropion | Propafenone | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. | Moderate | 1 | [
[
[
593,
24,
371
]
],
[
[
593,
63,
847
],
[
847,
1,
371
]
],
[
[
593,
64,
704
],
[
704,
1,
371
]
],
[
[
593,
63,
772
],
[
772,
40,
... | [
[
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propafenone"
]
],
[
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atomoxetine"
],
[
... | Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Atomoxetine and Atomoxetine (Compound) resembles Propafenone (Compound)
Bupropion may lead to a major life threatening interaction when taken with Fentanyl and Fentanyl (Compound) resembles Propafenone (Compound)
Bupropion may cau... |
DB00862 | DB09080 | 1,005 | 144 | [
"DDInter1918",
"DDInter1331"
] | Vardenafil | Olodaterol | Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and an oral therapy for the treatment of erectile dysfunction.[L45563,L45568] During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, ... | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
1005,
24,
144
]
],
[
[
1005,
25,
1011
],
[
1011,
24,
144
]
],
[
[
1005,
64,
11
],
[
11,
24,
144
]
],
[
[
1005,
63,
543
],
[
543,
... | [
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Vardenafil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod... | Vardenafil may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Vardenafil may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderate inte... |
DB01181 | DB06643 | 1,532 | 1,136 | [
"DDInter906",
"DDInter500"
] | Ifosfamide | Denosumab | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Moderate | 1 | [
[
[
1532,
24,
1136
]
],
[
[
1532,
63,
1555
],
[
1555,
24,
1136
]
],
[
[
1532,
64,
1377
],
[
1377,
24,
1136
]
],
[
[
1532,
25,
1510
],
[
15... | [
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
... | Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Ifosfamide may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cau... |
DB00446 | DB12240 | 597 | 110 | [
"DDInter351",
"DDInter1485"
] | Chloramphenicol | Polatuzumab vedotin | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable link... | Moderate | 1 | [
[
[
597,
24,
110
]
],
[
[
597,
24,
129
],
[
129,
23,
110
]
],
[
[
597,
24,
467
],
[
467,
24,
110
]
],
[
[
597,
63,
268
],
[
268,
24,... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzaluta... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Polatuzumab vedotin
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00209 | DB01122 | 352 | 158 | [
"DDInter1886",
"DDInter61"
] | Trospium | Ambenonium | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevu... | Ambenonium is a cholinesterase inhibitor. It is used in the management of myasthenia gravis. | Moderate | 1 | [
[
[
352,
24,
158
]
],
[
[
352,
35,
262
],
[
262,
24,
158
]
],
[
[
352,
24,
1507
],
[
1507,
24,
158
]
],
[
[
352,
24,
1511
],
[
1511,
... | [
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ambenonium"
]
],
[
[
"Trospium",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with ... | Trospium (Compound) resembles Clidinium (Compound) and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Ambenonium
Trospium may cause a moderate interaction that could exacerba... |
DB00030 | DB00903 | 1,685 | 1,680 | [
"DDInter934",
"DDInter686"
] | Insulin human | Etacrynic acid | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as ... | Moderate | 1 | [
[
[
1685,
24,
1680
]
],
[
[
1685,
24,
1572
],
[
1572,
23,
1680
]
],
[
[
1685,
24,
1669
],
[
1669,
62,
1680
]
],
[
[
1685,
24,
1021
],
[
10... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etacrynic acid"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Demeclocycline"
... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Demeclocycline and Demeclocycline may cause a minor interaction that can limit clinical effects when taken with Etacrynic acid
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Minoc... |
DB00620 | DB10316 | 175 | 334 | [
"DDInter1855",
"DDInter1248"
] | Triamcinolone | Mumps virus strain B level jeryl lynn live antigen | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease. | Major | 2 | [
[
[
175,
25,
334
]
],
[
[
175,
1,
617
],
[
617,
24,
334
]
],
[
[
175,
64,
1057
],
[
1057,
25,
334
]
],
[
[
175,
24,
1316
],
[
1316,
... | [
[
[
"Triamcinolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Budesonide"
],
[
"Budesonide",... | Triamcinolone (Compound) resembles Budesonide (Compound) and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Mumps virus strain B level jeryl lynn live antigen
Triamcinolone may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to ... |
DB00009 | DB10897 | 1,271 | 539 | [
"DDInter56",
"DDInter291"
] | Alteplase | Capsicum | Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplas... | Capsicum (Chili pepper) allergenic extract is used in allergenic testing. | Minor | 0 | [
[
[
1271,
23,
539
]
],
[
[
1271,
24,
885
],
[
885,
23,
539
]
],
[
[
1271,
25,
1226
],
[
1226,
23,
539
]
],
[
[
1271,
25,
1421
],
[
1421,
... | [
[
[
"Alteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
]
],
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
... | Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a minor interaction that can limit clinical effects when taken with Capsicum
Alteplase may lead to a major life threatening interaction when taken with Tirofiban and Tirofiban may cause a mi... |
DB00353 | DB06706 | 588 | 468 | [
"DDInter1187",
"DDInter985"
] | Methylergometrine | Isometheptene | A homolog of ergonovine containing one more CH2 group. (Merck Index, 11th ed) | Isometheptene is a sympathomimetic drug that causes vasoconstriction. It is used for treating migraines and tension headaches. | Major | 2 | [
[
[
588,
25,
468
]
],
[
[
588,
7,
2216
],
[
2216,
46,
468
]
],
[
[
588,
25,
1466
],
[
1466,
24,
468
]
],
[
[
588,
1,
1131
],
[
1131,
... | [
[
[
"Methylergometrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isometheptene"
]
],
[
[
"Methylergometrine",
"{u} (Compound) upregulates {v} (Gene)",
"PAK1"
],
[
"PAK1",
"{u} (Gene) is upregulated by {v} (C... | Methylergometrine (Compound) upregulates PAK1 (Gene) and PAK1 (Gene) is upregulated by Isometheptene (Compound)
Methylergometrine may lead to a major life threatening interaction when taken with Phenylpropanolamine and Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with I... |
DB00196 | DB06335 | 600 | 761 | [
"DDInter743",
"DDInter1646"
] | Fluconazole | Saxagliptin | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
600,
24,
761
]
],
[
[
600,
6,
7524
],
[
7524,
45,
761
]
],
[
[
600,
21,
28722
],
[
28722,
60,
761
]
],
[
[
600,
23,
307
],
[
307,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Fluconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound... | Fluconazole (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Saxagliptin (Compound)
Fluconazole (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Saxagliptin (Compound)
Fluconazole may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafini... |
DB00791 | DB06643 | 132 | 1,136 | [
"DDInter1902",
"DDInter500"
] | Uracil mustard | Denosumab | Nitrogen mustard derivative of uracil. It is a alkylating antineoplastic agent that is used in lymphatic malignancies, and causes mainly gastrointestinal and bone marrow damage. | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Moderate | 1 | [
[
[
132,
24,
1136
]
],
[
[
132,
1,
970
],
[
970,
24,
1136
]
],
[
[
132,
25,
1377
],
[
1377,
24,
1136
]
],
[
[
132,
25,
1510
],
[
1510,
... | [
[
[
"Uracil mustard",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Uracil mustard",
"{u} (Compound) resembles {v} (Compound)",
"Fluorouracil"
],
[
"Fluorouracil",
"{u} may caus... | Uracil mustard (Compound) resembles Fluorouracil (Compound) and Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Uracil mustard may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could e... |
DB00982 | DB12332 | 1,517 | 1,619 | [
"DDInter991",
"DDInter1626"
] | Isotretinoin | Rucaparib | Isotretinoin is a retinoid derivative of vitamin A used in the treatment of severe recalcitrant acne.[Label] It was most widely marketed under the brand name Accutane, which has since been discontinued. Isotretinoin is associated with major risks in pregnancy and is therefore only available under the iPLEDGE program in... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
1517,
24,
1619
]
],
[
[
1517,
24,
1019
],
[
1019,
24,
1619
]
],
[
[
1517,
63,
1486
],
[
1486,
24,
1619
]
],
[
[
1517,
25,
943
],
[
943... | [
[
[
"Isotretinoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Isotretinoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
],
... | Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolo... |
DB00620 | DB01165 | 175 | 1,539 | [
"DDInter1855",
"DDInter1325"
] | Triamcinolone | Ofloxacin | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Major | 2 | [
[
[
175,
25,
1539
]
],
[
[
175,
64,
1467
],
[
1467,
1,
1539
]
],
[
[
175,
25,
945
],
[
945,
40,
1539
]
],
[
[
175,
25,
739
],
[
739,
... | [
[
[
"Triamcinolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ofloxacin"
]
],
[
[
"Triamcinolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxacin"
],
[
"Enoxacin",
"{u} ... | Triamcinolone may lead to a major life threatening interaction when taken with Enoxacin and Enoxacin (Compound) resembles Ofloxacin (Compound)
Triamcinolone may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Ofloxacin (Compound)
Triamcinolone may lead to ... |
DB11732 | DB12364 | 1,097 | 1,421 | [
"DDInter1027",
"DDInter200"
] | Lasmiditan | Betrixaban | Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.[L9338,L9356] It was also approved by the European Commission on August 17, 2022. Traditionally, the triptan class of anti-migraine medications (e.g. [sumatriptan]) have se... | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Moderate | 1 | [
[
[
1097,
24,
1421
]
],
[
[
1097,
63,
1513
],
[
1513,
24,
1421
]
],
[
[
1097,
24,
971
],
[
971,
24,
1421
]
],
[
[
1097,
64,
1039
],
[
1039... | [
[
[
"Lasmiditan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Lasmiditan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apremilast"
],
[
... | Lasmiditan may cause a moderate interaction that could exacerbate diseases when taken with Apremilast and Apremilast may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Lasmiditan may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilt... |
DB00348 | DB10344 | 254 | 992 | [
"DDInter1300",
"DDInter818"
] | Nitisinone | Ginger | Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin. | Ginger allergenic extract is used in allergenic testing. | Moderate | 1 | [
[
[
254,
24,
992
]
],
[
[
254,
24,
1297
],
[
1297,
63,
992
]
],
[
[
254,
24,
578
],
[
578,
24,
992
]
],
[
[
254,
63,
1018
],
[
1018,
... | [
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginger"
]
],
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
],
[
... | Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Ginger
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagr... |
DB01259 | DB11689 | 392 | 321 | [
"DDInter1024",
"DDInter1659"
] | Lapatinib | Selumetinib | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Activation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway. Results from clinical trials investigating ea... | Moderate | 1 | [
[
[
392,
24,
321
]
],
[
[
392,
25,
982
],
[
982,
63,
321
]
],
[
[
392,
25,
498
],
[
498,
24,
321
]
],
[
[
392,
63,
752
],
[
752,
24,... | [
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
]
],
[
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib"... | Lapatinib may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Lapatinib may lead to a major life threatening interaction when taken with Edoxaban and Edoxaban may cause a moderate interacti... |
DB00480 | DB10316 | 1,668 | 334 | [
"DDInter1035",
"DDInter1248"
] | Lenalidomide | Mumps virus strain B level jeryl lynn live antigen | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenali... | Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease. | Major | 2 | [
[
[
1668,
25,
334
]
],
[
[
1668,
64,
1057
],
[
1057,
25,
334
]
],
[
[
1668,
25,
1316
],
[
1316,
64,
334
]
],
[
[
1668,
25,
908
],
[
908,
... | [
[
[
"Lenalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Lenalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
... | Lenalidomide may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Lenalidomide may lead to a major life threatening interaction when taken with Durvalumab and Durvalu... |
DB08815 | DB11986 | 154 | 484 | [
"DDInter1104",
"DDInter648"
] | Lurasidone | Entrectinib | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
154,
24,
484
]
],
[
[
154,
24,
466
],
[
466,
62,
484
]
],
[
[
154,
63,
222
],
[
222,
23,
484
]
],
[
[
154,
24,
1662
],
[
1662,
2... | [
[
[
"Lurasidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Lurasidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[... | Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Si... |
DB00446 | DB12010 | 597 | 214 | [
"DDInter351",
"DDInter785"
] | Chloramphenicol | Fostamatinib | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
597,
24,
214
]
],
[
[
597,
24,
723
],
[
723,
24,
214
]
],
[
[
597,
24,
861
],
[
861,
63,
214
]
],
[
[
597,
63,
10
],
[
10,
24,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Ripretini... |
DB00916 | DB01001 | 112 | 688 | [
"DDInter1202",
"DDInter1632"
] | Metronidazole | Salbutamol | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Minor | 0 | [
[
[
112,
23,
688
]
],
[
[
112,
6,
8374
],
[
8374,
45,
688
]
],
[
[
112,
21,
28714
],
[
28714,
60,
688
]
],
[
[
112,
23,
1247
],
[
1247,
... | [
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salbutamol"
]
],
[
[
"Metronidazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Metronidazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Salbutamol (Compound)
Metronidazole (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Salbutamol (Compound)
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazo... |
DB08868 | DB14711 | 1,011 | 779 | [
"DDInter737",
"DDInter1680"
] | Fingolimod | Smallpox (Vaccinia) Vaccine, Live | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | The New York City Board of Health strain of _Vaccinia_ is a viral strain used as a component of some smallpox vaccinations. ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain. | Major | 2 | [
[
[
1011,
25,
779
]
],
[
[
1011,
64,
1064
],
[
1064,
25,
779
]
],
[
[
1011,
25,
1259
],
[
1259,
25,
779
]
],
[
[
1011,
25,
994
],
[
994,
... | [
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cl... | Fingolimod may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Fingolimod may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a m... |
DB00424 | DB00924 | 19 | 1,405 | [
"DDInter896",
"DDInter454"
] | Hyoscyamine | Cyclobenzaprine | Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimus... | Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961 and has been available for human use since 1977. It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond.[A185039,A184... | Moderate | 1 | [
[
[
19,
24,
1405
]
],
[
[
19,
63,
1302
],
[
1302,
1,
1405
]
],
[
[
19,
24,
358
],
[
358,
1,
1405
]
],
[
[
19,
24,
401
],
[
401,
63,
... | [
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Protriptyline"
]... | Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Protriptyline and Protriptyline (Compound) resembles Cyclobenzaprine (Compound)
Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine (Compound) resembles Cyclo... |
DB09083 | DB14723 | 880 | 159 | [
"DDInter996",
"DDInter1026"
] | Ivabradine | Larotrectinib | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus r... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
880,
24,
159
]
],
[
[
880,
24,
98
],
[
98,
24,
159
]
],
[
[
880,
63,
597
],
[
597,
24,
159
]
],
[
[
880,
64,
1181
],
[
1181,
24,... | [
[
[
"Ivabradine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Ivabradine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
... | Ivabradine may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Ivabradine may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Ch... |
DB08881 | DB08883 | 868 | 1,597 | [
"DDInter1925",
"DDInter1428"
] | Vemurafenib | Perampanel | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Perampanel is a noncompetitive AMPA glutamate receptor antagonist. It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures. The FDA label includes an important black-boxed warning ... | Moderate | 1 | [
[
[
868,
24,
1597
]
],
[
[
868,
64,
609
],
[
609,
23,
1597
]
],
[
[
868,
63,
272
],
[
272,
24,
1597
]
],
[
[
868,
64,
1487
],
[
1487,
... | [
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perampanel"
]
],
[
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clar... | Vemurafenib may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Perampanel
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorph... |
DB00196 | DB13007 | 600 | 1,060 | [
"DDInter743",
"DDInter642"
] | Fluconazole | Enfortumab vedotin | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protea... | Moderate | 1 | [
[
[
600,
24,
1060
]
],
[
[
600,
24,
129
],
[
129,
23,
1060
]
],
[
[
600,
25,
1593
],
[
1593,
24,
1060
]
],
[
[
600,
23,
14
],
[
14,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
... | Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
Fluconazole may lead to a major life threatening interaction when taken with Crizotinib and Crizotini... |
DB00500 | DB01166 | 24 | 477 | [
"DDInter1831",
"DDInter379"
] | Tolmetin | Cilostazol | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Moderate | 1 | [
[
[
24,
24,
477
]
],
[
[
24,
7,
3727
],
[
3727,
46,
477
]
],
[
[
24,
18,
16896
],
[
16896,
57,
477
]
],
[
[
24,
21,
28688
],
[
28688,
... | [
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Tolmetin",
"{u} (Compound) upregulates {v} (Gene)",
"MAL"
],
[
"MAL",
"{u} (Gene) is upregulated by {v} (Compound)... | Tolmetin (Compound) upregulates MAL (Gene) and MAL (Gene) is upregulated by Cilostazol (Compound)
Tolmetin (Compound) downregulates IARS2 (Gene) and IARS2 (Gene) is downregulated by Cilostazol (Compound)
Tolmetin (Compound) causes Epistaxis (Side Effect) and Epistaxis (Side Effect) is caused by Cilostazol (Compound)
To... |
DB00099 | DB00305 | 440 | 377 | [
"DDInter735",
"DDInter1232"
] | Filgrastim | Mitomycin | Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the seq... | Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of th... | Moderate | 1 | [
[
[
440,
24,
377
]
],
[
[
440,
24,
450
],
[
450,
63,
377
]
],
[
[
440,
24,
552
],
[
552,
24,
377
]
],
[
[
440,
63,
599
],
[
599,
24,... | [
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mitomycin"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclophosphamide"
],
... | Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Carmustine... |
DB00975 | DB08931 | 1,317 | 947 | [
"DDInter573",
"DDInter1600"
] | Dipyridamole | Riociguat | A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurre... | Major | 2 | [
[
[
1317,
25,
947
]
],
[
[
1317,
24,
714
],
[
714,
24,
947
]
],
[
[
1317,
63,
1061
],
[
1061,
24,
947
]
],
[
[
1317,
63,
746
],
[
746,
... | [
[
[
"Dipyridamole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Riociguat"
]
],
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
[
"Iloprost"... | Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Riociguat
Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Trepr... |
DB00687 | DB00754 | 870 | 157 | [
"DDInter747",
"DDInter696"
] | Fludrocortisone | Ethotoin | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to ... | Moderate | 1 | [
[
[
870,
24,
157
]
],
[
[
870,
24,
759
],
[
759,
40,
157
]
],
[
[
870,
21,
28698
],
[
28698,
60,
157
]
],
[
[
870,
1,
167
],
[
167,
... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethotoin"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
],
... | Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone (Compound) resembles Ethotoin (Compound)
Fludrocortisone (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Ethotoin (Compound)
Fludrocortisone (Compound) resembles Hydro... |
DB00023 | DB00744 | 305 | 1,288 | [
"DDInter127",
"DDInter1962"
] | Asparaginase Escherichia coli | Zileuton | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Leukotrienes are substances that induce numerous biological effects including augmentation of neutrophil and eosinophil migration, neutrophil and monocyte aggregation, leukocyte adhesion, increased capillary permeability, and smooth muscle contraction. These effects contribute to inflammation, edema, mucus secretion, a... | Moderate | 1 | [
[
[
305,
24,
1288
]
],
[
[
305,
24,
482
],
[
482,
24,
1288
]
],
[
[
305,
24,
187
],
[
187,
63,
1288
]
],
[
[
305,
25,
1510
],
[
1510,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zileuton"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}"... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Zileuton
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases w... |
DB00427 | DB01186 | 1,233 | 107 | [
"DDInter1879",
"DDInter1430"
] | Triprolidine | Pergolide | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of Parkinson’s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic tr... | Moderate | 1 | [
[
[
1233,
24,
107
]
],
[
[
1233,
6,
12523
],
[
12523,
45,
107
]
],
[
[
1233,
24,
832
],
[
832,
24,
107
]
],
[
[
1233,
63,
1594
],
[
1594,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pergolide"
]
],
[
[
"Triprolidine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound... | Triprolidine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Pergolide (Compound)
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Pergolide
Triproli... |
DB10583 | DB11817 | 949 | 1,259 | [
"DDInter415",
"DDInter165"
] | Clostridium tetani toxoid antigen (formaldehyde inactivated) | Baricitinib | Clostridium tetani toxoid antigen (formaldehyde inactivated) is a vaccine for intramuscular injection. It is used for active immunization of children 7 years of age or older, and adults, for prevention of tetanus. The toxoid in the Clostridium tetani culture is grown and detoxified followed by purification via ammonium... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Moderate | 1 | [
[
[
949,
24,
1259
]
],
[
[
949,
63,
384
],
[
384,
25,
1259
]
],
[
[
949,
24,
1619
],
[
1619,
64,
1259
]
],
[
[
949,
24,
351
],
[
351,
... | [
[
[
"Clostridium tetani toxoid antigen (formaldehyde inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Baricitinib"
]
],
[
[
"Clostridium tetani toxoid antigen (formaldehyde inactivated)",
"{u} may cause a moderat... | Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Baricitinib
Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a mod... |
DB05528 | DB11730 | 1,070 | 351 | [
"DDInter1228",
"DDInter1588"
] | Mipomersen | Ribociclib | Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. M... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
1070,
25,
351
]
],
[
[
1070,
25,
283
],
[
283,
62,
351
]
],
[
[
1070,
64,
372
],
[
372,
24,
351
]
],
[
[
1070,
25,
1613
],
[
1613,
... | [
[
[
"Mipomersen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Mipomersen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} m... | Mipomersen may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Mipomersen may lead to a major life threatening interaction when taken with Clofarabine and Clofarabine may cause a moderate inte... |
DB01232 | DB05812 | 1,327 | 1,374 | [
"DDInter1640",
"DDInter8"
] | Saquinavir | Abiraterone | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Major | 2 | [
[
[
1327,
25,
1374
]
],
[
[
1327,
6,
10417
],
[
10417,
45,
1374
]
],
[
[
1327,
21,
29113
],
[
29113,
60,
1374
]
],
[
[
1327,
24,
466
],
[
... | [
[
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abiraterone"
]
],
[
[
"Saquinavir",
"{u} (Compound) binds {v} (Gene)",
"ABCC1"
],
[
"ABCC1",
"{u} (Gene) is bound by {v} (Compound)",
"Abirater... | Saquinavir (Compound) binds ABCC1 (Gene) and ABCC1 (Gene) is bound by Abiraterone (Compound)
Saquinavir (Compound) causes Hypokalaemia (Side Effect) and Hypokalaemia (Side Effect) is caused by Abiraterone (Compound)
Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide ... |
DB01050 | DB13620 | 848 | 948 | [
"DDInter900",
"DDInter1499"
] | Ibuprofen | Potassium gluconate | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Potassium gluconate is a salt of and is classified as a food additive by the FDA . It is also used as a potassium supplement . Potassium is an essential nutrient. It is the most abundant cation in the intracellular fluid, where it plays a key role in maintaining cell function . In dietary supplements, potassium is ofte... | Moderate | 1 | [
[
[
848,
24,
948
]
],
[
[
848,
63,
1027
],
[
1027,
24,
948
]
],
[
[
848,
64,
886
],
[
886,
24,
948
]
],
[
[
848,
74,
1274
],
[
1274,
... | [
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Potassium gluconate"
]
],
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Piroxicam"
],
... | Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Piroxicam and Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Potassium gluconate
Ibuprofen may lead to a major life threatening interaction when taken with Ketorolac and Ketorolac may cau... |
DB00690 | DB01612 | 1,216 | 1,637 | [
"DDInter762",
"DDInter92"
] | Flurazepam | Amyl Nitrite | A benzodiazepine derivative used mainly as a hypnotic. | Amyl Nitrite is an antihypertensive medicine. Amyl nitrite is employed medically to treat heart diseases such as angina and to treat cyanide poisoning. Its use as a prescription medicine comes from its ability to lower blood pressure. As an inhalant, it also has psychoactive effect which has led to illegal drug use. | Moderate | 1 | [
[
[
1216,
24,
1637
]
],
[
[
1216,
64,
475
],
[
475,
24,
1637
]
],
[
[
1216,
24,
401
],
[
401,
24,
1637
]
],
[
[
1216,
40,
1382
],
[
1382,
... | [
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Flurazepam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",... | Flurazepam may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may caus... |
DB04865 | DB12500 | 4 | 283 | [
"DDInter1335",
"DDInter714"
] | Omacetaxine mepesuccinate | Fedratinib | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Major | 2 | [
[
[
4,
25,
283
]
],
[
[
4,
24,
351
],
[
351,
23,
283
]
],
[
[
4,
63,
1419
],
[
1419,
24,
283
]
],
[
[
4,
24,
761
],
[
761,
24,
... | [
[
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
... | Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when take... |
DB01254 | DB08903 | 1,213 | 996 | [
"DDInter484",
"DDInter170"
] | Dasatinib | Bedaquiline | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Major | 2 | [
[
[
1213,
25,
996
]
],
[
[
1213,
6,
8374
],
[
8374,
45,
996
]
],
[
[
1213,
21,
29282
],
[
29282,
60,
996
]
],
[
[
1213,
62,
112
],
[
112,
... | [
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
]
],
[
[
"Dasatinib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Bedaquil... | Dasatinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bedaquiline (Compound)
Dasatinib (Compound) causes Arrhythmia (Side Effect) and Arrhythmia (Side Effect) is caused by Bedaquiline (Compound)
Dasatinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Me... |
DB01197 | DB06292 | 1,603 | 549 | [
"DDInter292",
"DDInter474"
] | Captopril | Dapagliflozin | Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment ... | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Moderate | 1 | [
[
[
1603,
24,
549
]
],
[
[
1603,
24,
1344
],
[
1344,
40,
549
]
],
[
[
1603,
6,
12523
],
[
12523,
45,
549
]
],
[
[
1603,
21,
28882
],
[
288... | [
[
[
"Captopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Captopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
... | Captopril may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Captopril (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Dapagliflozin (Compound)
Captopril (Compound) causes Body temperature increased (... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.